Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by
loss of upper and lower motor neurons, resulting in progressive weakness of all voluntary …

Introduction/Aims In amyotrophic lateral sclerosis (ALS) caused by superoxide dismutase 1 (SOD1)
gene mutations (SOD1‐ALS), the antisense oligonucleotide tofersen had been …

Background Spinal muscular atrophy (SMA) is a genetic neuromuscular disease caused by
mutations of the SMN1 gene. Deficient SMN protein causes irreversible degeneration of …

5q-associated spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) are
two distinct neurological disorders leading to degeneration of lower motor neurons. The …

Background In April 2023, the antisense oligonucleotide tofersen was approved by the US
Food and Drug Administration (FDA) for treatment of SOD1-amyotrophic lateral sclerosis (ALS…

Objective: The palmomental reflex (PMR) is commonly interpreted as a frontal release sign,
but it has also been discussed as a clinical marker of motoneuron affection in amyotrophic …

Tofersen is the first effective and approved therapy for familial ALS caused by pathogenic
variants in the SOD1 gene. Following treatment with tofersen, neurofilaments in patients CSF …

Background Myotonic dystrophy type 1 (Steinert’s disease or DM1), the most common form
of autosomal dominant muscular dystrophy in adults, is a multisystem disorder, affecting …

A 68-year-old man presented with progressive asymmetric limb weakness and muscle
wasting over 12 months. There were profuse fasciculations and hyperreflexia in the limbs and …

Discussion. Since Mills' original description, 1 few additional cases have been reported. 2
The scarcity of reports and lack of pathologic data raised doubt about the authenticity of this …